,,ii ,calendar ,no4 #chh #aadth ,,congress #b;d ,session ,s4 #bjee ,,in ,,the ,,senate ,,of ,,the ,,united ,,states ,september #ag1 #bjae,mr4 ,burr 7for himself1 ,mr4 ,casey1 ,mr4 ,isakson1 and ,mr4 ,roberts7 introduced the following bill2 which was read twice and referred to the ,committee on ,health1 ,education1 ,labor1 and ,pensions ,march #ad1 #bjaf,reported by ,mr4 ,alexander1 with an amendment,strike out all after the enacting clause and insert the part printed in italic ,a ,,bill ,to amend the ,public ,health ,service ,act and the ,federal ,food1 ,drug1 and ,cosmetic ,act with respect to national health security4 #a4 ,short title ,this ,act may be cited as the ,medical ,countermeasure ,innovation ,act of #bjae4 #b4 ,medical countermeasure guidelines 7a7 ,strategic national stockpile and security countermeasure procurements ,section #cai;,f-#b of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bdg;d-#f;b7 is amended-- 7#a7 in subsection 7a71 by adding at the end the following3 7#c7 ,utilization guidelines ,the ,secretary shall ensure timely and accurate recommended utilization guidelines for qualified countermeasures 7as defined in section #cai;,f-#a71 qualified pandemic and epidemic products 7as defined in section #cai;,f-#c71 and security countermeasures 7as defined in subsection 7c771 including for such products in the stockpile4 2 and 7#b7 in subsection 7g7-- 7,a7 by amending paragraph 7#d7 to read as follows3 7#d7 ,report on security countermeasure procurement ,not later than ,march #a of each year in which the ,secretary determines that the amount of funds available for procurement of security countermeasures is less than #a1ejj1jjj1jjj1 the ,secretary shall submit to the ,committee on ,appropriations and the ,committee on ,health1 ,education1 ,labor1 and ,pensions of the ,senate and the ,committee on ,appropriations and the ,committee on ,energy and ,commerce of the ,house of ,representatives a report detailing the amount of such funds available for procurement and the impact such amount of funding will have-- 7,a7 in meeting the security countermeasure needs identified under this section2 and 7,b7 on the annual ,public ,health ,emergency ,medical ,countermeasures ,enterprise and ,strategy ,implementation ,plan 7pursuant to section #bhaa7;d774 4 #c4 ,clarification on ,,barda contracting authority 7a7 ,in general ,section #cai;,f-#b7;g7 of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bdg;d-#f;b7g77 is amended by adding at the end the following3 7#e7 ,clarification on contracting authority ,the ,secretary1 acting through the ,director of the ,biomedical ,advanced ,research and ,development ,authority1 shall carry out the programs funded by the special reserve fund 7for the procurement of security countermeasures under subsection 7c7 and for carrying out section #cai,l71 including the execution of procurement contracts1 grants1 and cooperative agreements pursuant to this section and section #cai,l4 4 7b7 ,,barda contracting authority ,section #cai,l7c77#c7 of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bdg;d-#g;c7 is amended by inserting 1 including the execution of procurement contracts1 grants1 and cooperative agreements pursuant to this section before the period4 #d4 ,countermeasures budget plan ,section #bhaa7;b77#g7 of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #cjj;hh-#aj7;b77#g77 is amended-- 7#a7 by striking the first sentence and inserting ,develop1 and update not later than ,march #a of each year1 a coordinated #e-year budget plan based on the medical countermeasure priorities described in subsection 7d71 including with respect to chemical1 biological1 radiological1 and nuclear agent or agents that may present a threat to the ,nation1 including such agents that are novel or emerging infectious diseases1 and the corresponding efforts to develop qualified countermeasures 7as defined in section #cai;,f-#a71 security countermeasures 7as defined in section #cai;,f-#b71 and qualified pandemic or epidemic products 7as defined in section #cai;,f-#c7 for each such threat42 7#b7 in subparagraph 7,c71 by striking 2 and and inserting a semicolon2 7#c7 in subparagraph 7,d71 by striking to the appropriate committees of ,congress upon request4 and inserting 1 not later than ,march #ae of each year1 to the ,committee on ,appropriations and the ,committee on ,health1 ,education1 ,labor1 and ,pensions of the ,senate and the ,committee on ,appropriations and the ,committee on ,energy and ,commerce of the ,house of ,representatives2 and2 and 7#d7 by adding at the end the following3 7,e7 not later than ,march #ae of each year1 be made publicly available4 4 #e4 ,prioritizing the animal rule guidance ,section #efe7;c7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cfj;bbb-#d7;c77 is amended by adding at the end the following3 7#c7 ,written explanation ,the ,secretary shall provide to the ,committee on ,health1 ,education1 ,labor1 and ,pensions of the ,senate and the ,committee on ,energy and ,commerce of the ,house of ,representatives a written explanation1 not later than the last day of each month after the date of enactment of the ,medical ,countermeasure ,innovation ,act of #bjae in which the ,secretary fails to finalize such guidance1 for why the ,secretary has failed to finalize the guidance as required by this subsection4 4 #f4 ,streamlining the project bioshield procurement process ,section #cai;,f-#b7;c7 of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bdg;d-#f;b7c77 is amended-- 7#a7 in paragraph 7#d77;,a77ii71 by striking make a recommendation under paragraph 7#f7 that the special reserve fund as defined in subsection 7h7 be made available for the procurement of such countermeasure and inserting make available the special reserve fund as defined in subsection 7h7 for procurement of such countermeasure1 as applicable2 7#b7 in paragraph 7#f7-- 7,a7 by striking subparagraphs 7,a71 7,b71 and 7,e72 7,b7 by redesignating subparagraphs 7,c7 and 7,d7 as subparagraphs 7,a7 and 7,b71 respectively2 7,c7 by amending subparagraph 7,a71 as so redesignated1 to read as follows3 7,a7 ,notice to appropriate congressional committees ,the ,secretary shall notify the ,committee on ,appropriations and the ,committee on ,health1 ,education1 ,labor1 and ,pensions of the ,senate and the ,committee on ,appropriations and the ,committee on ,energy and ,commerce of the ,house of ,representatives of each decision to make available the special reserve fund as defined in subsection 7h7 for procurement of a security countermeasure1 including1 where available1 the number of1 the nature of1 and other information concerning potential suppliers of such countermeasure1 and whether other potential suppliers of the same or similar countermeasures were considered and rejected for procurement under this section and the reasons therefore4 2 and 7,d7 in the heading1 by striking ,recommendation for president's approval and inserting ,recommendations for procurement2 and 7#c7 in paragraph 7#g7-- 7,a7 by striking subparagraph 7,a72 7,b7 by striking subparagraph 7,b7 and inserting the following3 7,a7 ,payments from special reserve fund ,the special reserve fund as defined in subsection 7h7 shall be available for payments made by the ,secretary to a vendor for procurement of a security countermeasure in accordance with the provisions of this paragraph4 2 and 7,c7 by redesignating subparagraph 7,c7 as subparagraph 7,b74 #g4 ,priority review to encourage treatments for agents that present national security threats ,subchapter ,e of chapter ,v of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cfj;bbb et seq47 is amended by inserting after section #efe the following3 #efe;,a4 ,priority review to encourage treatments for agents that present national security threats 7a7 ,definitions ,in this section3 7#a7 ,the term priority review with respect to a human drug application as defined in section #gce7a71 means review and action by the ,secretary on such application not later than #f months after receipt by the ,secretary of such application1 as described in the ,manual of ,policies and ,procedures in the ,food and ,drug ,administration and goals identified in the letters described in section #aja7;b7 of the ,food and ,drug ,administration ,safety and ,innovation ,act4 7#b7 ,priority review voucher ,the term priority review voucher means a voucher issued by the ,secretary to the sponsor of a material threat medical countermeasure application that entitles the holder of such voucher to priority review of a single human drug application submitted under section #eje7;b77#a7 or section #cea of the ,public ,health ,service ,act after the date of approval of the material threat medical countermeasure application4 7#c7 ,material threat medical countermeasure application ,the term material threat medical countermeasure application means an application that-- 7,a7 is a human drug application as defined in section #gce7a7-- 7i7 to prevent1 or treat harm from a biological1 chemical1 radiological1 or nuclear agent identified as a material threat under section #cai;,f-#b7;c77#b77;,a77ii7 of the ,public ,health ,service ,act1 or 7ii7 to mitigate1 prevent1 or treat harm from a condition that may result in adverse health consequences or death and may be caused by administering a drug1 or biological product against such agent2 7,b7 the ,secretary deems eligible for priority review2 7,c7 is approved after the date of enactment of the ,medical ,countermeasure ,innovation ,act of #bjae2 and 7,d7 is for a human drug1 no active ingredient 7including any ester or salt of the active ingredient7 of which has been approved in any other application under section #eje7;b77#a7 or section #cea of the ,public ,health ,service ,act4 7b7 ,priority review voucher 7#a7 ,in general ,the ,secretary shall award a priority review voucher to the sponsor of a material threat medical countermeasure application upon approval by the ,secretary of such material threat medical countermeasure application4 7#b7 ,transferability ,the sponsor of a material threat medical countermeasure application that receives a priority review voucher under this section may transfer 7including by sale7 the entitlement to such voucher to a sponsor of a human drug for which an application under section #eje7;b77#a7 or section #cea of the ,public ,health ,service ,act will be submitted after the date of the approval of the material threat medical countermeasure application4 ,there is no limit on the number of times a priority review voucher may be transferred before such voucher is used4 7#c7 ,notification 7,a7 ,in general ,the sponsor of a human drug application shall notify the ,secretary not later than #ij calendar days prior to submission of the human drug application that is the subject of a priority review voucher of an intent to submit the human drug application1 including the date on which the sponsor intends to submit the application4 ,such notification shall be a legally binding commitment to pay for the user fee to be assessed in accordance with this section4 7,b7 ,transfer after notice ,the sponsor of a human drug application that provides notification of the intent of such sponsor to use the voucher for the human drug application under subparagraph 7,a7 may transfer the voucher after such notification is provided1 if such sponsor has not yet submitted the human drug application described in the notification4 7c7 ,priority review user fee 7#a7 ,in general ,the ,secretary shall establish a user fee program under which a sponsor of a human drug application that is the subject of a priority review voucher shall pay to the ,secretary a fee determined under paragraph 7#b74 ,such fee shall be in addition to any fee required to be submitted by the sponsor under chapter ,,vii4 7#b7 ,fee amount ,the amount of the priority review user fee shall be determined each fiscal year by the ,secretary and based on the average cost incurred by the agency in the review of a human drug application subject to priority review in the previous fiscal year4 7#c7 ,annual fee setting ,the ,secretary shall establish1 before the beginning of each fiscal year beginning after ,september #cj1 #bjae1 for that fiscal year1 the amount of the priority review user fee4 7#d7 ,payment 7,a7 ,in general ,the priority review user fee required by this subsection shall be due upon the submission of a human drug application under section #eje7;b77#a7 or section #cea of the ,public ,health ,service ,act for which the priority review voucher is used4 7,b7 ,complete application ,an application described under subparagraph 7,a7 for which the sponsor requests the use of a priority review voucher shall be considered incomplete if the fee required by this subsection and all other applicable user fees are not paid in accordance with the ,secretary's procedures for paying such fees4 7,c7 ,no waivers1 exemptions1 reductions1 or refunds ,the ,secretary may not grant a waiver1 exemption1 reduction1 or refund of any fees due and payable under this section4 7#e7 ,offsetting collections ,fees collected pursuant to this subsection for any fiscal year-- 7,a7 shall be deposited and credited as offsetting collections to the account providing appropriations to the ,food and ,drug ,administration2 and 7,b7 shall not be collected for any fiscal year except to the extent provided in advance in appropriation ,acts4 7d7 ,notice of ,issuance of ,voucher and ,approval of ,products ,under ,voucher ,the ,secretary shall publish a notice in the ,federal ,register and on the ,internet ,website of the ,food and ,drug ,administration not later than #cj calendar days after the occurrence of each of the following3 7#a7 ,the ,secretary issues a priority review voucher under this section4 7#b7 ,the ,secretary approves a drug pursuant to an application submitted under section #eje7;b7 of this ,act or section #cea7;a7 of the ,public ,health ,service ,act for which the sponsor of the application used a priority review voucher under this section4 7e7 ,eligibility for other programs ,nothing in this section precludes a sponsor who seeks a priority review voucher under this section from participating in any other incentive program1 including under this ,act1 except that no sponsor of a material threat medical countermeasure application may receive more than one priority review voucher with respect to such drug4 7f7 ,relation to other provisions ,the provisions of this section shall supplement1 not supplant1 any other provisions of this ,act or the ,public ,health ,service ,act that encourage the development of medical countermeasures4 4 #a4 ,short title ,this ,act may be cited as the ,medical ,countermeasure ,innovation ,act of #bjaf4 #b4 ,medical countermeasure guidelines 7a7 ,strategic national stockpile and security countermeasure procurements ,section #cai;,f-#b of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bdg;d-#f;b7 is amended-- 7#a7 in subsection 7a71 by adding at the end the following3 7#c7 ,utilization guidelines ,the ,secretary shall ensure timely and accurate recommended utilization guidelines for qualified countermeasures 7as defined in section #cai;,f-#a71 qualified pandemic and epidemic products 7as defined in section #cai;,f-#c71 and security countermeasures 7as defined in subsection 7c771 including for such products in the stockpile4 2 and 7#b7 in subsection 7g7-- 7,a7 by amending paragraph 7#d7 to read as follows3 7#d7 ,report on security countermeasure procurement ,not later than ,march #a of each year in which the ,secretary determines that the amount of funds available for procurement of security countermeasures is less than #a1ejj1jjj1jjj1 the ,secretary shall submit to the ,committee on ,appropriations and the ,committee on ,health1 ,education1 ,labor1 and ,pensions of the ,senate and the ,committee on ,appropriations and the ,committee on ,energy and ,commerce of the ,house of ,representatives a report detailing the amount of such funds available for procurement and the impact such amount of funding will have-- 7,a7 in meeting the security countermeasure needs identified under this section2 and 7,b7 on the annual ,public ,health ,emergency ,medical ,countermeasures ,enterprise and ,strategy ,implementation ,plan 7pursuant to section #bhaa7;d774 2 and #c4 ,clarification on ,,barda contracting authority 7a7 ,in general ,section #cai;,f-#b7;g7 of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bdg;d-#f;b7g77 is amended by adding at the end the following3 7#e7 ,clarification on contracting authority ,the ,secretary1 acting through the ,director of the ,biomedical ,advanced ,research and ,development ,authority1 shall carry out the programs funded by the special reserve fund 7for the procurement of security countermeasures under subsection 7c7 and for carrying out section #cai,l71 including the execution of procurement contracts1 grants1 and cooperative agreements pursuant to this section and section #cai,l4 4 7b7 ,,barda contracting authority ,section #cai,l7c77#c7 of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bdg;d-#g;c7 is amended by inserting 1 including the execution of procurement contracts1 grants1 and cooperative agreements pursuant to this section before the period4 #d4 ,countermeasures budget plan ,section #bhaa7;b77#g7 of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #cjj;hh-#aj7;b77#g77 is amended-- 7#a7 by striking the first sentence and inserting ,develop1 and update not later than ,march #a of each year1 a coordinated #e-year budget plan based on the medical countermeasure priorities described in subsection 7d71 including with respect to chemical1 biological1 radiological1 and nuclear agent or agents that may present a threat to the ,nation1 including such agents that are novel or emerging infectious diseases1 and the corresponding efforts to develop qualified countermeasures 7as defined in section #cai;,f-#a71 security countermeasures 7as defined in section #cai;,f-#b71 and qualified pandemic or epidemic products 7as defined in section #cai;,f-#c7 for each such threat42 7#b7 in subparagraph 7,c71 by striking 2 and and inserting a semicolon2 7#c7 in subparagraph 7,d71 by striking to the appropriate committees of ,congress upon request4 and inserting 1 not later than ,march #ae of each year1 to the ,committee on ,appropriations and the ,committee on ,health1 ,education1 ,labor1 and ,pensions of the ,senate and the ,committee on ,appropriations and the ,committee on ,energy and ,commerce of the ,house of ,representatives2 and2 and 7#d7 by adding at the end the following3 7,e7 not later than ,march #ae of each year1 be made publicly available in a manner that does not compromise national security4 4 #e4 ,medical countermeasures innovation ,section #cai,l7c77#d7 of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bdg;d-#g;e7c77#d77 is amended by adding at the end the following3 7,e7 ,medical countermeasures innovation partner 7i7 ,in general ,to support the purposes described in paragraph 7#b71 the ,secretary1 acting through the ,director of ,,barda1 may enter into an agreement 7including through the use of grants1 contracts1 cooperative agreements1 or other transactions as described in paragraph 7#e77 with an independent1 non-profit entity to-- 7,i7 foster and accelerate the development and innovation of medical countermeasures and technologies that may assist advanced research and development of qualified countermeasures and qualified pandemic or epidemic products1 including through the use of strategic venture capital practices and methods2 7,,ii7 promote the development of new and promising technologies that address urgent medical countermeasure needs1 as identified by the ,secretary2 7,,iii7 address unmet public health needs that are directly related to medical countermeasure requirements1 such as novel antimicrobials for multidrug resistant organisms and multiuse platform technologies for diagnostics1 prophylaxis1 vaccines1 and therapeutics2 and 7,,iv7 provide expert consultation and advice to foster viable medical countermeasure innovators1 including helping qualified countermeasure innovators navigate unique industry challenges with respect to developing chemical1 biological1 radiological1 and nuclear countermeasure products4 7ii7 ,eligibility 7,i7 ,in general ,to be eligible to enter into an agreement under clause 7i7 an entity shall-- 7aa7 be an independent1 non-profit entity2 7bb7 have a demonstrated record of being able to create linkages between innovators and investors and leverage such partnerships and resources for the purpose of addressing identified strategic needs of the ,federal ,government2 7cc7 have experience in promoting novel technology innovation2 7dd7 be problem driven and solution focused based on the needs1 requirements1 and problems identified by the ,secretary under clause 7iv72 7ee7 demonstrate the ability1 or the potential ability1 to promote the development of medical countermeasure products2 7ff7 demonstrate expertise1 or the capacity to develop or acquire expertise1 related to technical and regulatory considerations with respect to medical countermeasures2 and 7gg7 not be within the ,department of ,health and ,human ,services4 7,,ii7 ,partnering experience ,in selecting an entity with which to enter into an agreement under clause 7i71 the ,secretary shall place a high value on the demonstrated experience of the entity in partnering with the ,federal ,government to meet identified strategic needs4 7iii7 ,not agency ,an entity that enters into an agreement under clause 7i7 shall not be deemed to be a ,federal agency for any purpose1 including for any purpose under title #e1 ,united ,states ,code4 7iv7 ,direction ,pursuant to an agreement entered into under this subparagraph1 the ,secretary1 acting through the ,director of ,,barda1 shall provide direction to the entity that enters into an agreement under clause 7i74 ,as part of this agreement the ,director of ,,barda shall-- 7,i7 communicate the medical countermeasure needs1 requirements1 and problems to be addressed by the entity under the agreement2 7,,ii7 develop a description of work to be performed by the entity under the agreement2 7,,iii7 provide technical feedback and appropriate oversight over work carried out by the entity under the agreement1 including subsequent development and partnerships consistent with the needs and requirements set forth in this subparagraph2 7,,iv7 ensure fair consideration of products developed under the agreement in order to maintain competition to the maximum practical extent1 as applicable and appropriate under applicable provisions of this section2 and 7,v7 ensure1 as a condition of the agreement-- 7aa7 a comprehensive set of policies that demonstrate a commitment to transparency and accountability2 7bb7 protection against conflicts of interest through a comprehensive set of policies that address potential conflicts of interest1 ethics1 disclosure1 and reporting requirements2 7cc7 that the entity provides monthly accounting on the use of funds provided under such agreement2 and 7dd7 that the entity provides on a quarterly basis1 reports regarding the progress made toward meeting the identified needs set forth in the agreement4 7v7 ,supplement not supplant ,activities carried out under this subparagraph shall supplement1 and not supplant1 other activities carried out under this section4 7vi7 ,no establishment of entity ,to prevent unnecessary duplication and target resources effectively1 nothing in this subparagraph shall be construed to authorize the ,secretary to establish within the ,department of ,health and ,human ,services an entity for the purposes of carrying out this subparagraph4 7vii7 ,transparency and oversight ,upon request1 the ,secretary shall provide to ,congress the information provided to the ,secretary under clause 7iv77,v77dd74 7viii7 ,independent evaluation ,not later than #d years after the date of enactment of this subparagraph1 the ,government ,accountability ,office shall conduct an independent evaluation1 and submit to the ,secretary and the appropriate committees of ,congress a report1 concerning the activities conducted under this subparagraph4 ,such report shall include recommendations with respect to any agreement or activities carried out pursuant to this subparagraph4 7ix7 ,sunset ,this subparagraph shall have no force or effect after ,september #cj1 #bjbb4 4 #f4 ,streamlining the project bioshield procurement process ,section #cai;,f-#b7;c7 of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bdg;d-#f;b7c77 is amended-- 7#a7 in paragraph 7#d77;,a77ii71 by striking make a recommendation under paragraph 7#f7 that the special reserve fund as defined in subsection 7h7 be made available for the procurement of such countermeasure and inserting and subject to the availability of appropriations1 make available the special reserve fund as defined in subsection 7h7 for procurement of such countermeasure1 as applicable2 7#b7 in paragraph 7#f7-- 7,a7 by striking subparagraphs 7,a71 7,b71 and 7,e72 7,b7 by redesignating subparagraphs 7,c7 and 7,d7 as subparagraphs 7,a7 and 7,b71 respectively2 7,c7 by amending subparagraph 7,a71 as so redesignated1 to read as follows3 7,a7 ,notice to appropriate congressional committees ,the ,secretary shall notify the ,committee on ,appropriations and the ,committee on ,health1 ,education1 ,labor1 and ,pensions of the ,senate and the ,committee on ,appropriations and the ,committee on ,energy and ,commerce of the ,house of ,representatives of each decision to make available the special reserve fund as defined in subsection 7h7 for procurement of a security countermeasure1 including1 where available1 the number of1 the nature of1 and other information concerning potential suppliers of such countermeasure1 and whether other potential suppliers of the same or similar countermeasures were considered and rejected for procurement under this section and the reasons therefore4 2 and 7,d7 in the heading1 by striking ,recommendation for president's approval and inserting ,recommendations for procurement2 and 7#c7 in paragraph 7#g7-- 7,a7 by striking subparagraph 7,a72 7,b7 by striking subparagraph 7,b7 and inserting the following3 7,a7 ,payments from special reserve fund ,the special reserve fund as defined in subsection 7h7 shall be available for payments made by the ,secretary to a vendor for procurement of a security countermeasure in accordance with the provisions of this paragraph4 2 and 7,c7 by redesignating subparagraph 7,c7 as subparagraph 7,b74 #g4 ,priority review to encourage treatments for agents that present national security threats ,subchapter ,e of chapter ,v of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cfj;bbb et seq47 is amended by inserting after section #efe the following3 #efe;,a4 ,priority review to encourage treatments for agents that present national security threats 7a7 ,definitions ,in this section3 7#a7 ,the term priority review with respect to a human drug application as defined in section #gce7a71 means review and action by the ,secretary on such application not later than #f months after receipt by the ,secretary of such application1 as described in the ,manual of ,policies and ,procedures in the ,food and ,drug ,administration and goals identified in the letters described in section #aja7;b7 of the ,food and ,drug ,administration ,safety and ,innovation ,act4 7#b7 ,priority review voucher ,the term priority review voucher means a voucher issued by the ,secretary to the sponsor of a material threat medical countermeasure application that entitles the holder of such voucher to priority review of a single human drug application submitted under section #eje7;b77#a7 or section #cea7;a7 of the ,public ,health ,service ,act after the date of approval of the material threat medical countermeasure application4 7#c7 ,material threat medical countermeasure application ,the term material threat medical countermeasure application means an application that-- 7,a7 is a human drug application as defined in section #gce7a7-- 7i7 to prevent1 or treat harm from a biological1 chemical1 radiological1 or nuclear agent identified as a material threat under section #cai;,f-#b7;c77#b77;,a77ii7 of the ,public ,health ,service ,act1 or 7ii7 to mitigate1 prevent1 or treat harm from a condition that may result in adverse health consequences or death and may be caused by administering a drug1 or biological product against such agent2 and 7,b7 the ,secretary deems eligible for priority review2 7,c7 is approved after the date of enactment of the ,medical ,countermeasure ,innovation ,act of #bjaf2 and 7,d7 is for a human drug1 no active ingredient 7including any ester or salt of the active ingredient7 of which has been approved in any other application under section #eje7;b77#a7 or section #cea7;a7 of the ,public ,health ,service ,act4 7b7 ,priority review voucher 7#a7 ,in general ,the ,secretary shall award a priority review voucher to the sponsor of a material threat medical countermeasure application upon approval by the ,secretary of such material threat medical countermeasure application4 7#b7 ,transferability ,the sponsor of a material threat medical countermeasure application that receives a priority review voucher under this section may transfer 7including by sale7 the entitlement to such voucher to a sponsor of a human drug for which an application under section #eje7;b77#a7 or section #cea7;a7 of the ,public ,health ,service ,act will be submitted after the date of the approval of the material threat medical countermeasure application4 ,there is no limit on the number of times a priority review voucher may be transferred before such voucher is used4 7#c7 ,notification 7,a7 ,in general ,the sponsor of a human drug application shall notify the ,secretary not later than #ij calendar days prior to submission of the human drug application that is the subject of a priority review voucher of an intent to submit the human drug application1 including the date on which the sponsor intends to submit the application4 ,such notification shall be a legally binding commitment to pay for the user fee to be assessed in accordance with this section4 7,b7 ,transfer after notice ,the sponsor of a human drug application that provides notification of the intent of such sponsor to use the voucher for the human drug application under subparagraph 7,a7 may transfer the voucher after such notification is provided1 if such sponsor has not yet submitted the human drug application described in the notification4 7c7 ,priority review user fee 7#a7 ,in general ,the ,secretary shall establish a user fee program under which a sponsor of a human drug application that is the subject of a priority review voucher shall pay to the ,secretary a fee determined under paragraph 7#b74 ,such fee shall be in addition to any fee required to be submitted by the sponsor under chapter ,,vii4 7#b7 ,fee amount ,the amount of the priority review user fee shall be determined each fiscal year by the ,secretary and based on the average cost incurred by the agency in the review of a human drug application subject to priority review in the previous fiscal year4 7#c7 ,annual fee setting ,the ,secretary shall establish1 before the beginning of each fiscal year beginning after ,september #cj1 #bjae1 for that fiscal year1 the amount of the priority review user fee4 7#d7 ,payment 7,a7 ,in general ,the priority review user fee required by this subsection shall be due upon the submission of a human drug application under section #eje7;b77#a7 or section #cea7;a7 of the ,public ,health ,services ,act for which the priority review voucher is used4 7,b7 ,complete application ,an application described under subparagraph 7,a7 for which the sponsor requests the use of a priority review voucher shall be considered incomplete if the fee required by this subsection and all other applicable user fees are not paid in accordance with the ,secretary's procedures for paying such fees4 7,c7 ,no waivers1 exemptions1 reductions1 or refunds ,the ,secretary may not grant a waiver1 exemption1 reduction1 or refund of any fees due and payable under this section4 7#e7 ,offsetting collections ,fees collected pursuant to this subsection for any fiscal year-- 7,a7 shall be deposited and credited as offsetting collections to the account providing appropriations to the ,food and ,drug ,administration2 and 7#f7 shall not be collected for any fiscal year except to the extent provided in advance in appropriation ,acts4 7d7 ,notice of ,issuance of ,voucher and ,approval of ,products ,under ,voucher ,the ,secretary shall publish a notice in the ,federal ,register and on the ,internet ,website of the ,food and ,drug ,administration not later than #cj calendar days after the occurrence of each of the following3 7#a7 ,the ,secretary issues a priority review voucher under this section4 7#b7 ,the ,secretary approves a drug pursuant to an application submitted under section #eje7;b7 of this ,act or section #cea7;a7 of the ,public ,health ,service ,act for which the sponsor of the application used a priority review voucher under this section4 7e7 ,eligibility for other programs ,nothing in this section precludes a sponsor who seeks a priority review voucher under this section from participating in any other incentive program1 including under this ,act1 except that no sponsor of a material threat medical countermeasure application may receive more than one priority review voucher issued under any section of this ,act with respect to such drug4 7f7 ,relation to other provisions ,the provisions of this section shall supplement1 not supplant1 any other provisions of this ,act or the ,public ,health ,service ,act that encourage the development of medical countermeasures4 4 #h4 ,,gao report 7a7 ,study ,the ,comptroller ,general of the ,united ,states shall conduct a study on the effectiveness of priority review vouchers under section #efe;,a of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7as added by section #g7 in providing incentives for the development of material threat medical countermeasures applications under such section #efe;,a4 ,in conducting such study1 the ,comptroller ,general shall examine the following3 7#a7 ,the impact of the priority review voucher in attracting investment into the development of material threat medical countermeasures and the impact of such investment1 as applicable1 on the development of such countermeasures4 7#b7 ,how the drugs for which priority review vouchers were awarded under such section #efe;,a-- 7,a7 addressed identified medical countermeasure needs2 and 7,b7 impacted ,united ,states preparedness against chemical1 biological1 radiological1 and nuclear threats1 including both identified threats and naturally-occurring threats4 7#c7 ,how many material threat medical countermeasures were licensed or approved1 or otherwise significantly advanced in clinical development1 in the #aj years following the enactment of such section #efe;,a compared to the #aj years prior to the enactment of such section4 7#d7 ,an analysis of the drugs for which such priority review vouchers were used1 which shall include-- 7,a7 the indications for which such drugs were approved under section #eje7;b77#a7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cee7 or section #cea7;a7 of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bfb72 7,b7 whether unmet medical needs were addressed through the approval of such drugs1 including1 for each such drug-- 7i7 if an alternative therapy was previously available to treat the indication2 and 7ii7 if the drug provided a benefit or advantage over another available therapy2 7,c7 the value of the priority review voucher if transferred2 and 7,d7 the length of time between the date on which a priority review voucher was awarded and the date on which it was used4 7#e7 ,with respect to the priority review voucher program under such section #efe;,a-- 7,a7 how many priority review vouchers were awarded under such section #efe;,a and how many of such awarded vouchers were redeemed for priority review of a drug application in the #aj years following the date of enactment of such section2 7,b7 the resources associated with the ,food and ,drug ,administration implementation of such section #efe;,a and review of applications for which a voucher awarded under such section #efe;,a is redeemed for priority review2 and 7,c7 recommendations1 if any1 with respect to how such section #efe;,a could be improved to better achieve the objective of incentivizing the timely development of medical countermeasures to address identified chemical1 biological1 radiological1 and nuclear threats1 including for medical countermeasures that might otherwise not be developed1 potentially eligible for an emergency use authorization1 licensed1 or approved4 7b7 ,consultations ,in conducting the study under subsection 7a71 the ,comptroller ,general of the ,united ,states shall consult with-- 7#a7 drug manufacturers involved in the research and development of medical countermeasures to address biological1 chemical1 radiological1 and nuclear threats2 7#b7 stakeholders involved in investing in the research and development of medical countermeasures1 including venture capitalists2 7#c7 the ,federal ,government agencies responsible for advancing1 reviewing1 and procuring medical countermeasures1 including-- 7,a7 the ,department of ,health and ,human ,services1 including the ,office of the ,assistant ,secretary for ,preparedness and ,response1 the ,biomedical ,advanced ,research and ,development ,authority1 and the ,food and ,drug ,administration2 and 7,b7 the ,department of ,defense2 and 7#d7 biodefense stakeholders1 as applicable4 7c7 ,initial assessment ,not later than #g years after the date of enactment of this ,act1 the ,comptroller ,general of the ,united ,states shall submit to the ,committee on ,health1 ,education1 ,labor1 and ,pensions of the ,senate and the ,committee on ,energy and ,commerce of the ,house of ,representatives an initial assessment of the effectiveness of the priority review voucher program set forth in section #efe;,a of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7as added by section #g74 7d7 ,report ,not later than #ab years after the date of enactment of this ,act1 the ,comptroller ,general of the ,united ,states shall submit to the ,committee on ,health1 ,education1 ,labor1 and ,pensions of the ,senate and the ,committee on ,energy and ,commerce of the ,house of ,representatives a report containing the results of the study conducted under subsection 7a74 7e7 ,protection of national security ,the ,comptroller ,general of the ,united ,states shall conduct the study and issue the assessment and report under this section in a manner that does not compromise national security4 ,march #ad1 #bjaf,reported with an amendment